Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR2 Mutant Neoplasms | Preclinical | United States | 01 Mar 2024 | |
FGFR3 Mutant Neoplasms | Preclinical | United States | 01 Mar 2024 |